Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Down 5.29%
As of Friday, July 31, Palvella Therapeutics, Inc.’s PVLA share price has dipped by 5.29%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Commentary & Analysis
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.23%
As of Tuesday, July 21, Palvella Therapeutics, Inc.’s PVLA share price has surged by 5.23%, which has investors questioning if this is right time to sell.Michael Rose
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 13.35%
As of Tuesday, July 21, Palvella Therapeutics, Inc.’s PVLA share price has surged by 13.35%, which has investors questioning if this is right time to sell.Tudor Pop
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Down 7.06%
As of Monday, July 20, Palvella Therapeutics, Inc.’s PVLA share price has dipped by 7.06%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Down 14.48%
As of Monday, July 20, Palvella Therapeutics, Inc.’s PVLA share price has dipped by 14.48%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,994.2 | $252.6 | 54% |
|
| Shares Out (Mil) | 13.1 | 52.3 | 24% |
|
| Institutional Ownership | 90.7% | 92.1% | 59% |
|
| Float (Mil) | 9.6 | 40.2 | 19% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 219 | 455 | 46% |
|
| Price Change (52-week) |
271.4% | 52.9% | 98% |
|
| Growth | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 13 | 10 | |
| Current EPS | ($1.156) | ($5.565) | ($6.384) | |
| Month Ago EPS | ($1.156) | ($5.565) | ($6.818) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 2 | |
| Three Months Ago EPS | ($1.048) | ($5.145) | ($6.389) | |
| Year/Year Chg | (4.1%) | 50.1% | 8.1% | |
| Financials | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($49) | ($43) | 16% |
|
| EPS (TTM) | ($4.189) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($29) | ($31) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $20 | $5 | 33% |
|
| Enterprise Value (Q1) (Mil) | $1,463 | $180 | 46% |
|
| Valuation | PVLA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.57 | 2.56 | 88% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (28.7%) | (49.8%) | 17% |
|
| ROE | (34.2%) | (55.5%) | 19% |
|
| Liabilities to Assets | 11.9% | 30.3% | 7% |
|
| F-Score | 2 | 3 | 7% |
|
Palvella Therapeutics, Inc. did not pass any screens on 7/31/2026.
